US2017159015A1PendingUtilityA1

Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells

57
Assignee: CORNELL RES FOUNDATION INCPriority: Feb 15, 2002Filed: Feb 14, 2017Published: Jun 8, 2017
Est. expiryFeb 15, 2022(expired)· nominal 20-yr term from priority
Inventors:Steven A. GoldmanNeeta Singh RoyMartha Windrem
A61P 43/00A61P 7/04G01N 33/5005C12N 2510/00C12N 5/0618A61P 25/00A61P 27/02C12N 5/0622C12N 5/0623A61K 35/12G01N 33/56966A61K 35/30C12N 5/0619A61P 29/00A61P 31/04A61K 48/00Y02A50/30
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . An isolated population of human cells, said population enriched for A2B5 + /PSA-NCAM − glial progenitor cells. 
     
     
         3 . The isolated population of  claim 2 , wherein the human is an adult. 
     
     
         4 . The isolated population of  claim 2 , wherein the human is post-natal. 
     
     
         5 . The isolated population of  claim 2 , wherein the human is fetal. 
     
     
         6 . The isolated population of  claim 2 , wherein at least 90% of the population comprises A2B5 + /PSA-NCAM −  glial progenitor cells. 
     
     
         7 . The isolated population of  claim 2 , wherein at least 95% of the population comprises A2B5 + /PSA-NCAM −  glial progenitor cells. 
     
     
         8 . The isolated population of  claim 2 , wherein at least 99% of the population comprises A2B5 + /PSA-NCAM −  glial progenitor cells. 
     
     
         9 . The isolated population of  claim 2 , wherein the glial progenitor cells are oligodendrocyte progenitor cells (OPCs). 
     
     
         10 . The isolated population of  claim 2 , wherein the population contains uncommitted progenitor cells.

Join the waitlist — get patent alerts

Track US2017159015A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.